Evidence map›Paper›PMID 38575965›Full record

ArticleBehavioral and brain functions : BBF2024

Loss of GDE2 leads to complex behavioral changes including memory impairment.

Daniel Daudelin, Anna Westerhaus, Nan Zhang, Erica Leyder, Alena Savonenko, Shanthini Sockanathan

Open access · goldAbstract read
In one paragraph

Article in Behavioral and brain functions : BBF, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniel Daudelin *The Solomon Snyder Department of Neuroscience, The Johns Hopkins School of Medicine, PCTB 1004, 725 N. Wolfe Street, Baltimore, MD, 21205, USA.
Anna Westerhaus *The Solomon Snyder Department of Neuroscience, The Johns Hopkins School of Medicine, PCTB 1004, 725 N. Wolfe Street, Baltimore, MD, 21205, USA.
Nan ZhangThe Solomon Snyder Department of Neuroscience, The Johns Hopkins School of Medicine, PCTB 1004, 725 N. Wolfe Street, Baltimore, MD, 21205, USA.
Erica LeyderDepartment of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Avenue, Baltimore, MD, 21205, USA.
Alena SavonenkoDepartment of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Avenue, Baltimore, MD, 21205, USA. alena.savonenko@nih.gov.
Shanthini SockanathanThe Solomon Snyder Department of Neuroscience, The Johns Hopkins School of Medicine, PCTB 1004, 725 N. Wolfe Street, Baltimore, MD, 21205, USA. ssockan1@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Training Program in NeuroscienceT32NS091018 · NINDS · JOHNS HOPKINS UNIVERSITY · PI JAMES J KNIERIM, Daniel Hans O'Connor · 2015 to 2026
$4.1M
Mechanisms of amyloid precursor protein processing: novel regulation of α-secretase activityRF1AG062671 · NIA · JOHNS HOPKINS UNIVERSITY · PI SOCKANATHAN, SHANTHINI · 2019 to 2019
$2.7M
Investigating pathways of hippocampal synaptic funtion: potential implications for Alzheimer's diseaseF31AG079539 · NIA · JOHNS HOPKINS UNIVERSITY · PI DAUDELIN, DANIEL · 2023 to 2025
$146k
NIA NIH HHS F31 AG079539NIA NIH HHS RF1 AG062671NIH HHS RF1AG062671NIH HHS T32GM007445NIH HHS T32NS091018NINDS NIH HHS T32 NS091018
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) and amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) are debilitating neurodegenerative diseases for which there are currently no cures. Familial cases with known genetic causes make up less than 10% of these diseases, and little is known about the underlying mechanisms that contribute to sporadic disease. Accordingly, it is important to expand investigations into possible pathways that may contribute to disease pathophysiology. Glycerophosphodiester phosphodiesterase 2 (GDE2 or GDPD5) is a membrane-bound enzyme that acts at the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers distinct proteins to the membrane. GDE2 abnormally accumulates in intracellular compartments in the brain of patients with AD, ALS, and ALS/FTD, indicative of GDE2 dysfunction. Mice lacking GDE2 (Gde2KO) show neurodegenerative changes such as neuronal loss, reduced synaptic proteins and synapse loss, and increased Aβ deposition, raising the possibility that GDE2 disruption in disease might contribute to disease pathophysiology. However, the effect of GDE2 loss on behavioral function and learning/memory has not been characterized.

resultsHere, we show that GDE2 is expressed throughout the adult mouse brain in areas including the cortex, hippocampus, habenula, thalamus, and amygdala. Gde2KO and WT mice were tested in a set of behavioral tasks between 7 and 16 months of age. Compared to WT, Gde2KO mice display moderate hyperactivity that becomes more pronounced with age across a variety of behavioral tests assessing novelty-induced exploratory activity. Additionally, Gde2KO mice show reduced startle response, with females showing additional defects in prepulse inhibition. No changes in anxiety-associated behaviors were found, but Gde2KOs show reduced sociability. Notably, aged Gde2KO mice demonstrate impaired short/long-term spatial memory and cued fear memory/secondary contextual fear acquisition.

conclusionsTaken together, these observations suggest that loss of GDE2 leads to behavioral deficits, some of which are seen in neurodegenerative disease models, implying that loss of GDE2 may be an important contributor to phenotypes associated with neurodegeneration.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisFrontotemporal DementiaNeurodegenerative DiseasesAgedAnimalsFemaleHumansMemoryMemory DisordersMiceMice, TransgenicPhosphoric Diester HydrolasesGDPD5 protein, humanglycerophosphodiester phosphodiesterasePhosphoric Diester HydrolasesBehaviorDiseaseGDE2HyperactivityMemory impairmentNeurodegeneration

Identifiers

PMID38575965
PMCPMC10993612
OpenAlexW4393929178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.